A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli M, Roy S, Newell R, Pestano L, Dickinson B, Rigby K, Herazo-Maya J, Jenkins G, Ian S, Saini G, Johnson SR, Braybrooke R, Yu G, Sauler M, Ahangari F, Ding S, DeIuliis J, Aurelien N, Montgomery RL, Kaminski N. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine 2022, 85: 104304. PMID: 36265417, PMCID: PMC9587275, DOI: 10.1016/j.ebiom.2022.104304.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisNon-human primatesPulmonary fibrosisAnimal modelsPro-fibrotic genesAnti-fibrotic efficacyMiR-29 mimicsHuman peripheral bloodMiR-29b levelsHuman lung fibroblastsIPF patientsIPF diagnosisPeripheral bloodReduced fibrosisAdverse findingsPotential therapyLung slicesTGF-β1Relevant dosesLung fibroblastsNIH-NHLBIFibrosisTherapyCollagen productionProfibrotic gene programSex differences and altered mitophagy in experimental pulmonary hypertension
Bazan IS, Kim SJ, Ardito TA, Zhang Y, Shan P, Sauler M, Lee P. Sex differences and altered mitophagy in experimental pulmonary hypertension. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2022, 322: l761-l769. PMID: 35137625, PMCID: PMC9076415, DOI: 10.1152/ajplung.00019.2020.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionPathogenesis of PHFemale-predominant diseaseRight heart failurePulmonary arterial pressureExperimental pulmonary hypertensionMitochondrial dysfunctionLung endothelial cellsSex differencesMouse lung endothelial cellsInhibition of ParkinArterial pressureHeart failurePulmonary arteryMitochondrial respiratory capacityPoor outcomeHigh prevalenceSevere diseaseAnimal modelsEndothelial cellsParkin expressionOxidative stressCell proliferationHypertensionSex